JUUL and other e-cigarette makers shouldn’t expect a reprieve from the FDA’s push on teen vaping with the Trump administration’s decision to put Ned Sharpless from the National Cancer Institute at the agency’s helm.
Health and Human Services Secretary Alex Azar confirmed Sharpless will be the acting commissioner of the Food and Drug Administration during a March 12 hearing before the House Energy and Commerce Committee. The announcement ends speculation about who would be next to run the agency after Scott Gottlieb announced March 5 he is resigning.
Sharpless’s appointment means the FDA likely won’t relent on the teen e-cigaratte ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.